Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Obagi Medical Products Inc. Stories

2013-10-29 08:32:46

SANTA BARBARA, Calif., Oct. 29, 2013 /PRNewswire/ -- Suneva Medical, Inc., a rapidly growing medical aesthetics company, announced today plans to expand its existing partnership with Obagi Medical Products, Inc. (Obagi). Suneva Medical distributes, and is the exclusive licensee for, the full line of ReGenica® skincare products, and Obagi currently co-distributes ReGenica Facial Rejuvenation Complex. Under the terms of the existing agreement between the two companies, Obagi will...

2013-10-21 23:19:02

Obagi Hydrate Luxe, a luxuriously rich night cream nurtures skin while you sleep, helping to sustain a young, beautiful complexion. Brooklyn, NY (PRWEB) October 21, 2013 Apothecarie.com announced that the addition of Obagi Hydrate Luxe to its selection of physician-recommended skin rejuvenating products. The night-time hydrating formula works to rejuvenate cells during sleep to erase the visible sign of aging. “Obagi Hydrate Luxe works with the user’s circadian rhythm to help the body...

2013-07-24 08:29:11

IRVINE, Calif., July 24, 2013 /PRNewswire/ -- ZO Skin Health, Inc. is pleased to announce that board-certified dermatologist and fellowship-trained cosmetic and laser surgeon, Monika Kiripolsky, M.D., FAAD, will present Dr. Zein Obagi's educational seminar, "Expanded Concepts and Principles of Skin Health Science," on August 22, 2013 at the Hyatt Regency O'Hare. As a member of the world-class multidisciplinary ZO® faculty, Dr. Kiripolsky will unveil ZO Skin Health, Inc. founder and...

2013-04-25 08:34:38

LAVAL, Quebec, April 25, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") for a price of $24 per share in cash, without interest (less any applicable withholding taxes). The Offer expired at midnight, New York...

2013-04-24 08:29:17

LAVAL, Quebec, April 24, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that it has received approval by the Antimonopoly Committee of Ukraine (the "AMC") of its proposed acquisition of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") pursuant to a tender offer and subsequent merger. The receipt of the AMC's approval of the acquisition satisfies one of the conditions to consummate the tender offer. As previously announced, the...

2013-04-23 08:33:49

LAVAL, Quebec, April 23, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced it has extended the expiration date of the tender offer by its indirect wholly-owned subsidiary, Odysseus Acquisition Corp., for all of the outstanding shares of common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") at a price of $24.00 per share, net to the seller in cash, without interest (less any required withholding taxes). The offer and withdrawal...

2013-04-22 08:28:57

MONTREAL, April 22, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Odysseus Acquisition Corp. ("Purchaser"), for all of the outstanding shares of common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") at a price of $24.00 per...

2013-04-08 08:29:58

FRANKFURT, Germany, April 8, 2013 /PRNewswire/ -- Merz Pharma Group ("Merz" or "the Company") today announced that it has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products, Inc. (NASDAQ-GS: OMPI) ("Obagi") for $22 per share in cash. The decision to withdraw the proposal follows the recent announcement that Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") increased its offer to acquire Obagi from...

2013-04-03 08:27:50

MONTREAL, April 3, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that Valeant and Obagi Medical Products, Inc. (NASDAQ: OMPI) have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash. The offer documents will be amended to reflect the new offer price of $24.00 per share. The expiration date...

2013-03-27 12:26:16

WILMINGTON, Del., March 27, 2013 /PRNewswire/ -- Rigrodsky & Long, P.A.: Do you own shares of Obagi Medical Products, Inc. (NASDAQ GS: OMPI)? Did you purchase any of your shares prior to March 20, 2013? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Obagi Medical Products, Inc. ("Obagi" or the "Company") (NASDAQ...